MLYS vs AAPG
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
MLYS · Mineralys Therapeutics$15.33 ▲ 0.59%
AAPG · Ascentage Pharma$15.43 ▲ 1.98%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- MLYS -65.6%
- AAPG -52.4%
Head to head
| Metric | MLYS | AAPG |
|---|---|---|
| Price | $15.33 | $15.43 |
| Change today | ▲ 0.59% | ▲ 1.98% |
| Market cap | $1.36B | $1.44B |
| Return, 3 months | -44.0% | -18.2% |
| Return, year to date | -57.8% | -41.2% |
| Return, 1 year | -59.7% | -51.4% |
| P/E (TTM) | – | – |
| P/B | 2.7 | 17.3 |
| P/E percentile vs own 5y | 79th | 99th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | -41.5% |
| Net profit growth (YoY) | -457.1% | -206.4% |
| Gross margin | – | 93.9% |
| Operating margin | – | -216.7% |
| Net margin | – | -228.5% |
| Return on equity | -80.9% | -240.3% |
| Analyst target vs. price | +212.2% | +172.2% |
| Analyst buy share | 86% | 100% |
| RSI (14) | 29 | 52 |
| 30-day volatility | 86.1% | 72.0% |
| Max drawdown, 1 year | -67.8% | -61.0% |
| Trend read | Strong downtrend | Leaning bullish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- AAPG is the largest of the group by market value.
- AAPG has returned the most over the past year.
- AAPG has been the calmest stock over the last 30 days.